View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
September 22, 2016

M&As this week: Allergan, Cannabis Care Canada

Allergan plans to expand its gastrointestinal research and development (R&D) pipeline and strengthen its position in non-alcoholic steatohepatitis through the acquisition of Tobira Therapeutics.

Allergan plans to expand its gastrointestinal research and development (R&D) pipeline and strengthen its position in non-alcoholic steatohepatitis through the acquisition of Tobira Therapeutics.

The company expects to complete the transaction by October 2016 at a cost of up to $1.6bn.

Cannabis Care Canada Inc has announced its acquirement of Mettrum Ltd from Mettrum Health Corporation for a purchase consideration of $5.3m.

Covington & Burling is acting as the legal advisor, while Centerview Partners and Citigroup Inc are acting as financial advisors to Allergan. SKadden, Arps, Slate, Meagher & Flom and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian are acting as legal advisors to Tobira Therapuetics.

Cannabis Care Canada Inc has announced its acquirement of Mettrum Ltd from Mettrum Health Corporation for a purchase consideration of $5.3m.

Pursuant to the acquisition, Mettrum will become a wholly owned subsidiary of CCC and will be renamed as Starseed Medicinal Inc.

The acquisition will allow Cannabis Care Canada to make cannabis treatment accessible to all of its members and their families.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena